Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

July

28

Exagen Inc. to Participate in Upcoming Investor Conference

CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing,...

21

Exagen to Announce Second Quarter Financial Results on August 4, 2026

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune...

1

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional...

11

Exagen Inc. Reports First Quarter 2026 Results

Delivers record total revenue and AVISE® CTD average selling price CARLSBAD, Calif., May 11, 2026 (GLOBE...

27

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Conference call at 8:30 a.m. ET (5:30 a.m. PT) CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) — Exagen...

10

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force...

11

Exagen Inc. Announces Select Preliminary 2025 Financial Results

CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing,...

11

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing,...

4

Exagen Inc. Reports Strong Q3 2025 Results

CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of...

23

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing,...

29

Exagen Inc. Reports Strong Q2 2025 Results

CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of...

17

Exagen Inc. Appoints Chas McKhann to Board of Directors

CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune...

Recent developments

News

July

28

Exagen Inc. to Participate in Upcoming Investor Conference

July

21

Exagen to Announce Second Quarter Financial Results on August 4, 2026

June

1

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

May

11

Exagen Inc. Reports First Quarter 2026 Results

April

27

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

March

10

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

January

11

Exagen Inc. Announces Select Preliminary 2025 Financial Results

November

11

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

November

4

Exagen Inc. Reports Strong Q3 2025 Results

October

23

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

July

29

Exagen Inc. Reports Strong Q2 2025 Results

July

17

Exagen Inc. Appoints Chas McKhann to Board of Directors